Page 43 - GHES-2-2

Global Health Econ Sustain MDR-TB and the road ahead

to identify key factors contributing to the catastrophic cost https://doi.org/10.1371/journal.pgph.0000805
of TB care in Pakistan. Journal of Tuberculosis Research, Meghji, J., Gregorius, S., Madan, J., Chitimbe, F., Thomson, R.,
8(4):181-198.
Rylance, J., et al. (2021). The long term effect of pulmonary
https://doi.org/10.4236/jtr.2020.84017 tuberculosis on income and employment in a low income,
Iradukunda, A., Ndayishimiye, G.P., Sinarinzi, D., Odjidja, EN., urban setting. Thorax, 76(4):387-395.
Ntakaburimvo, N., Nshimirimana, I., et al. (2021). Key https://doi.org/10.1136/thoraxjnl-2020-215338
factors influencing multidrug-resistant tuberculosis in Menzies, N.A., Allwood, B.W., Dean, A.S., Dodd, P.J.,
patients under anti-tuberculosis treatment in two centres Houben, R.M.G.J., James, L.P., et al. (2023). Global
in Burundi: A mixed effect modelling study. BMC Public burden of disease due to rifampicin-resistant tuberculosis:
Health, 21;2142.
A mathematical modeling analysis. Nature Communications,
https://doi.org/10.1186/s12889-021-12233-2 14(1):6182.

Ismail, N.A., Omar, S.V., Moultrie, H., Bhyat, Z., Conradie, F., https://doi.org/10.1038/s41467-023-41937-9
Enwerem, M., et al. (2022). Assessment of epidemiological Molla, K.A., Reta, M.A., & Ayene, Y.Y. (2022). Prevalence of
and genetic characteristics and clinical outcomes of
resistance to Bedaquiline in patients treated for rifampicin- multidrug-resistant tuberculosis in East Africa: A systematic
review and meta-analysis. PLoS One, 17(6):e0270272.
resistant tuberculosis: A cross-sectional and longitudinal
study. The Lancet Infectious Diseases, 22(4):496-506. https://doi.org/10.1371/journal.pone.0270272
https://doi.org/10.1016/S1473-3099(21)00470-9 Molla, Y., Jerene, D., Jemal, I., Nigussie, G., Kebede, T., Kassie, Y.,
et al. (2017). The experience of scaling up a decentralized,
Jang, J.G., & Chung, J.H. (2020). Diagnosis and treatment of ambulatory model of care for management of multidrug-
multidrug-resistant tuberculosis. Yeungnam University resistant tuberculosis in two regions of Ethiopia. Journal of
Journal of Medicine, 37(4):277-285.
Clinical Tuberculosis and Other Mycobacterial Diseases, 7:28-33.
https://doi.org/10.12701/yujm.2020.00626
https://doi.o10.1016/j.jctube.2017.03.001
Jiang, Y., Chen, J., Ying, M., Liu, L., Li, M., Lu, S., et al. (2023).
Factors associated with loss to follow-up before and after Monedero, I., & Caminero, J.A. (2013). Common errors in
multidrug-resistant tuberculosis management. Expert
treatment initiation among patients with tuberculosis: Review of Respiratory Medicine, 8(1):15-23.
A 5-year observation in China, Frontiers in Medicine
(Lausanne), 10:1136094. https://doi.org/10.1586/17476348.2014.856758
https://doi.org/10.3389/fmed.2023.1136094 Mulder, C., Rupert, S., Setiawan, E., Mambetova, E., Edo, P.,
Sugiharto, J., et al. (2022). Budgetary impact of using BPaL
Labuda, S.M., Seaworth, B., Dasgupta, S., & Goswami, N.D. for treating extensively drug-resistant tuberculosis. BMJ
(2024). Bedaquiline, pretomanid, and linezolid with
or without Moxifloxacin for tuberculosis. The Lancet Global Health, 7(1):e007182.
Respiratory Medicine, 12(2):e5-e6. https://doi.org/10.1136/bmjgh-2021-007182
https://doi.org/10.1016/S2213-2600(23)00426-5 Nyang’wa, B.T., Berry, C., Kazounis, E., Motta, I., Parpieva, N.,
Tigay, Z., et al. (2022). A 24-week, All-oral regimen for
Laurence, Y.V., Griffiths, U.K., & Vassall, A., (2015). Costs to Rifampin-Resistant Tuberculosis. The New England Journal
health services and the patient of treating tuberculosis:
A systematic literature review. Pharmacoeconomics, of Medicine, 387(25):2331-2343.
33(9):939-955. https://doi.org/10.1056/NEJMoa2117166
https://doi.org/10.1007/s40273-015-0279-6 Oliosi, J.G.N., Reis-Santos, B., Locatelli, R.L., Sales, C.M.M., da
Silva Filho, W.G., da Silva, K.C., et al. (2019). Effect of the
Makamure, B., Makumbirofa, S., Bandason, T., Leccese, P.,
Mutetwa, R., Robertson, V., et al. (2017). A suggested Bolsa Familia Programme on the outcome of tuberculosis
algorithm for detection of multi drug-resistant tuberculosis treatment: A prospective cohort study. The Lancet Global
in Zimbabwe. The Journal of Infection in Developing Health, 7(2):219-226.
Countries, 11(8):611-618. https://doi.org/10.1016/S2214-109X(18)30478-9
https://doi.org/10.3855/jidc.8009 Onorato, L., Gentile, V., Russo, A., Di Caprio, G., Alessio, L.,
Chiodini, P., et al. (2021). Standard versus high dose of
Maleche-Obimbo, E., Odhiambo, M.A., Njeri, L., Mburu, M.,
Jaoko, W., Were, F., et al. (2022). Magnitude and factors rifampicin in the treatment of pulmonary tuberculosis:
associated with post-tuberculosis lung disease in low- and A systematic review and meta-analysis. Clinical Microbiology
middle-income countries: A systematic review and meta- and Infection, 27(6):830-837.
analysis. PLoS Global Public Health, 2(12):e0000805. https://doi.org/10.1016/j.cmi.2021.03.031

Volume 2 Issue 2 (2024) 6 https://doi.org/10.36922/ghes.2876